1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Lymphocytic Leukemia (CLL) - Drugs In Development, 2022, provides an overview of the Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections that keep coming back (recur), loss of appetite or becoming full too quickly (early satiety) and weight loss. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Chronic Lymphocytic Leukemia (CLL) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 4, 6, 75, 111, 9, 16, 72, 11 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 10, 19, 15 and 6 molecules, respectively.
Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Chronic Lymphocytic Leukemia (CLL) - Overview
- Chronic Lymphocytic Leukemia (CLL) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development
- Chronic Lymphocytic Leukemia (CLL) - Drug Profiles
- Chronic Lymphocytic Leukemia (CLL) - Dormant Projects
- Chronic Lymphocytic Leukemia (CLL) - Discontinued Products
- Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, 2022
- Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, 2022
- Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- ABL Bio Inc
- Acerta Pharma BV
- Achelois Cell Therapy
- Actinium Pharmaceuticals Inc
- Actinobac Biomed Inc
- ADC Therapeutics SA
- Adlai Nortye Biopharma Co Ltd
- Advenchen Laboratories LLC
- AI Therapeutics Inc
- Alaunos Therapeutics Inc
- Alloplex Biotherapeutics Inc
- Amgen Inc
- Apotex Inc
- Ardan Pharma
- Ascenta Therapeutics Inc
- Ascentage Pharma Group International
- Astellas Pharma Inc
- AstraZeneca Plc
- Athenex Inc
- Aucentra Therapeutics Pty Ltd
- Autolus Therapeutics Plc
- Avesthagen Ltd
- AVM Biotechnology LLC
- BAKX Therapeutics Inc
- Bantam Pharmaceutical LLC
- Bayer AG
- BeiGene Ltd
- Beijing Gaobo Biotechnology Co Ltd
- Beijing GD Initiative Cell Therapy Technology Co Ltd
- Beijing Jingda Biotechnology Co Ltd
- Beijing Mabworks Biotech Co Ltd
- Bio-Path Holdings Inc
- Biocure Technology Inc
- Biogen Inc
- BioIntegrator
- Biomea Fusion Inc
- Bionomics Ltd
- BioNTech SE
- BioXpress Therapeutics SA
- Boryung Pharmaceutical Co Ltd
- Bristol-Myers Squibb Co
- Carna Biosciences Inc
- CARsgen Therapeutics Ltd
- CasInvent Pharma AS
- Catalent Inc
- Catapult Therapeutics BV
- Cellectar Biosciences Inc
- Cellular Biomedicine Group Inc
- Celularity Inc
- Century Therapeutics Inc
- Checkpoint Therapeutics Inc
- Chengdu Brilliant Pharmaceutical Co Ltd
- Chengdu Hyperway Pharmaceutical Co Ltd
- Chengdu Jinrui Foundation Biotechnology Co Ltd
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- Chimeric Therapeutics Ltd
- Chongqing Precision Biotech Co Ltd
- Clonz Biotech Pvt Ltd
- CoImmune Inc
- Conjupro Biotherapeutics Inc
- CrystalGenomics Inc
- CSPC Pharmaceutical Group Ltd
- Curis Inc
- Cyclacel Pharmaceuticals Inc
- Cyteir Therapeutics Inc
- Dren Bio Inc
- Eli Lilly and Co
- EntreChem SL
- Eternity Bioscience Inc
- Eureka Therapeutics Inc
- Evopoint Bioscience Co Ltd
- Excelmab Inc
- Exelixis Inc
- Exinda Therapeutics LLC
- F. Hoffmann-La Roche Ltd
- Fate Therapeutics Inc
- Fochon Pharmaceutical Ltd
- Galapagos NV
- GeneaMed Ltd
- Genentech USA Inc
- GenFleet Therapeutics (Shanghai) Inc
- Genmab AS
- Genor BioPharma Co Ltd
- Gilead Sciences Inc
- GLG Pharma SA
- Grid Therapeutics LLC
- Grifols SA
- Grupo Ferrer Internacional SA
- GSK plc
- GT Biopharma Inc
- Guangdong East Sunshine Pharmaceutical Co Ltd
- Guangzhou BeBetter Medicine Technology Co Ltd
- Guangzhou Bio-gene Technology Co Ltd
- Haisco Pharmaceutical Group Co Ltd
- Hangzhou Hezheng Pharmaceutical Co Ltd
- Hangzhou Minsheng Pharmaceutical Group Co Ltd
- Hangzhou Sumgen Biotech Co Ltd
- Hangzhou Zenshine Pharmaceuticals Co Ltd
- Hebei Senlang Biotechnology Co Ltd
- Heidelberg Pharma AG
- Helocyte Biosciences Inc
- HK inno.N Corp
- Hutchison MediPharma Ltd
- Hybrigenics SA
- iBio Inc
- IDP Discovery Pharma SL
- IGM Biosciences Inc
- Iksuda Therapeutics Ltd
- Immatics NV
- ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
- ImmuneTarget Inc
- ImmunityBio Inc
- Incyte Corp
- Inflection Biosciences Ltd
- InnoBation Bio
- InnoCare Pharma Ltd
- IO Biotech Inc
- Iovance Biotherapeutics Inc
- Jiangsu Maidu Drug Research and Development Co Ltd
- Johnson & Johnson
- Juventas Cell Therapy Ltd
- Kancera AB
- Kangpu Biopharmaceuticals Ltd
- Kartos Therapeutics Inc
- Karus Therapeutics Ltd
- Karyopharm Therapeutics Inc
- Kite Pharma Inc
- Lanzhou Institute of Biological Products Co Ltd
- LAVA Therapeutics NV
- LegoChem Biosciences Inc
- Light Chain Bioscience
- LintonPharm Co Ltd
- Loxo Oncology Inc
- LTZ Therapeutics Inc
- Mabion SA
- ManysmarT Therapeutics Inc
- MedPacto Inc
- MEI Pharma Inc
- MENTRIK Biotech LLC
- Merck & Co Inc
- Millennium Pharmaceuticals Inc
- Miltenyi Biomedicine GmbH
- Minghui Pharmaceutical (Shanghai) Co Ltd
- MingSight Pharmaceuticals Inc
- MiNK Therapeutics Inc
- MorphoSys AG
- Mustang Bio Inc
- Nanjing Aimeifei Biomedical Technology Co Ltd
- Nanjing Bioheng Biotech Co Ltd
- Nanjing Iaso Biotherapeutics Co Ltd
- Nanjing Sanhome Pharmaceutical Co Ltd
- Newave Pharmaceutical Inc
- Nichi-Iko Pharmaceutical Co Ltd
- Nordic Nanovector ASA
- NovalGen Ltd
- Novartis AG
- Nurix Therapeutics Inc
- Octapharma AG
- OncoTartis Inc
- Oncternal Therapeutics
- Ono Pharmaceutical Co Ltd
- Orano Med LLC
- PersonGen BioTherapeutics (Suzhou) Co Ltd
- Pfizer Inc
- Pharmapraxis
- PIQUR Therapeutics AG
- Plexxikon Inc
- Precigen Inc
- Precision Biosciences Inc
- Qilu Pharmaceutical Co Ltd
- Qilu Puget Sound Biotherapeutics Corp
- Remd Biotherapeutics Inc
- Repare Therapeutics Inc
- Rhizen Pharmaceuticals SA
- Sana Biotechnology Inc
- Sanofi
- Schrodinger Inc
- Secura Bio Inc
- SFA Therapeutics Inc
- Shandong New Time Pharmaceutical Co Ltd
- Shanghai Haiyan Pharmaceutical Technology Co Ltd
- Shanghai Simnova Biotechnology Co Ltd
- Shanghai YaKe Biotechnology Co Ltd
- Shanghai Yingli Pharmaceutical Co Ltd
- Shengke Pharmaceuticals (Jiangsu) Ltd
- Shenzhen Targetrx Inc
- Shouyao Holding Co Ltd
- Sian Wuhan Medical Technology Co Ltd
- Sino Biopharmaceutical Ltd
- Sorrento Therapeutics Inc
- SpecificiT Pharma Inc
- Starton Therapeutics Inc
- Supratek Pharma Inc
- Suzhou Fundamenta Therapeutics Co Ltd
- Suzhou JiSheng Pharmaceutical Co Ltd
- Swedish Orphan Biovitrum AB
- Systimmune Inc
- Takeda Pharmaceutical Co Ltd
- Targazyme Inc
- TC BioPharm Ltd
- Telios Pharma Inc
- TG Therapeutics Inc
- Tiannuojiancheng Pharma
- TransThera Sciences (Nanjing) Inc
- Ubix Therapeutics Inc
- United BioPharma Inc
- Vincerx Pharma Inc
- Viridian Therapeutics Inc
- Wuhan Bio-Raid Biotechnology Co Ltd
- XEME BioPharma Inc
- Xencor Inc
- Xi'An Yufan Biotechnology Co Ltd
- Zhejiang DTRM Biopharma LLC
- Zhejiang Hisun Pharmaceutical Co Ltd
- Zhejiang Longchuan Biomedical Technology Co Ltd
- Zhejiang Teruisi Pharmaceutical Co Ltd
- Zhengda Tianqing Pharmaceutical Group Co Ltd
- Zibo Baiji Changsheng Pharmaceutical Co Ltd
- Zylem Biosciences Inc
